208 related articles for article (PubMed ID: 21504710)
1. Advances in the understanding of constitutional and somatic genomic alterations in neuroblastoma.
Deyell RJ; Attiyeh EF
Cancer Genet; 2011 Mar; 204(3):113-21. PubMed ID: 21504710
[TBL] [Abstract][Full Text] [Related]
2. Genetics and genomics of neuroblastoma.
Capasso M; Diskin SJ
Cancer Treat Res; 2010; 155():65-84. PubMed ID: 20517688
[TBL] [Abstract][Full Text] [Related]
3. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma.
Janoueix-Lerosey I; Lequin D; Brugières L; Ribeiro A; de Pontual L; Combaret V; Raynal V; Puisieux A; Schleiermacher G; Pierron G; Valteau-Couanet D; Frebourg T; Michon J; Lyonnet S; Amiel J; Delattre O
Nature; 2008 Oct; 455(7215):967-70. PubMed ID: 18923523
[TBL] [Abstract][Full Text] [Related]
4. Global genomic and RNA profiles for novel risk stratification of neuroblastoma.
Ohira M; Nakagawara A
Cancer Sci; 2010 Nov; 101(11):2295-301. PubMed ID: 20731666
[TBL] [Abstract][Full Text] [Related]
5. Oncogenic mutations of ALK kinase in neuroblastoma.
Chen Y; Takita J; Choi YL; Kato M; Ohira M; Sanada M; Wang L; Soda M; Kikuchi A; Igarashi T; Nakagawara A; Hayashi Y; Mano H; Ogawa S
Nature; 2008 Oct; 455(7215):971-4. PubMed ID: 18923524
[TBL] [Abstract][Full Text] [Related]
6. Oncogenic mutations of ALK in neuroblastoma.
Ogawa S; Takita J; Sanada M; Hayashi Y
Cancer Sci; 2011 Feb; 102(2):302-8. PubMed ID: 21205076
[TBL] [Abstract][Full Text] [Related]
7. Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number.
Wang Q; Diskin S; Rappaport E; Attiyeh E; Mosse Y; Shue D; Seiser E; Jagannathan J; Shusterman S; Bansal M; Khazi D; Winter C; Okawa E; Grant G; Cnaan A; Zhao H; Cheung NK; Gerald W; London W; Matthay KK; Brodeur GM; Maris JM
Cancer Res; 2006 Jun; 66(12):6050-62. PubMed ID: 16778177
[TBL] [Abstract][Full Text] [Related]
8. ArrayCGH-based classification of neuroblastoma into genomic subgroups.
Michels E; Vandesompele J; De Preter K; Hoebeeck J; Vermeulen J; Schramm A; Molenaar JJ; Menten B; Marques B; Stallings RL; Combaret V; Devalck C; De Paepe A; Versteeg R; Eggert A; Laureys G; Van Roy N; Speleman F
Genes Chromosomes Cancer; 2007 Dec; 46(12):1098-108. PubMed ID: 17823929
[TBL] [Abstract][Full Text] [Related]
9. Appearance of the novel activating F1174S ALK mutation in neuroblastoma correlates with aggressive tumor progression and unresponsiveness to therapy.
Martinsson T; Eriksson T; Abrahamsson J; Caren H; Hansson M; Kogner P; Kamaraj S; Schönherr C; Weinmar J; Ruuth K; Palmer RH; Hallberg B
Cancer Res; 2011 Jan; 71(1):98-105. PubMed ID: 21059859
[TBL] [Abstract][Full Text] [Related]
10. Microarray-based DNA profiling to study genomic aberrations.
Waddell N
IUBMB Life; 2008 Jul; 60(7):437-40. PubMed ID: 18553550
[TBL] [Abstract][Full Text] [Related]
11. [Identification of the breakpoint-flanking markers on chromosomes 1 and 17 of a constitutional translocation T(1;17)(P36;Q12-21) in a patient with neuroblastoma].
Laureys GG
Verh K Acad Geneeskd Belg; 1995; 57(5):389-422. PubMed ID: 8571670
[TBL] [Abstract][Full Text] [Related]
12. Advances in the translational genomics of neuroblastoma: From improving risk stratification and revealing novel biology to identifying actionable genomic alterations.
Bosse KR; Maris JM
Cancer; 2016 Jan; 122(1):20-33. PubMed ID: 26539795
[TBL] [Abstract][Full Text] [Related]
13. Molecular characterization and classification of neuroblastoma.
Oberthuer A; Theissen J; Westermann F; Hero B; Fischer M
Future Oncol; 2009 Jun; 5(5):625-39. PubMed ID: 19519203
[TBL] [Abstract][Full Text] [Related]
14. The evolution of clinical molecular genetics. Neuroblastoma as a model tumor.
Israel MA
Am J Pediatr Hematol Oncol; 1986; 8(2):163-72. PubMed ID: 3526938
[TBL] [Abstract][Full Text] [Related]
15. Expression of the tumour suppressor gene CADM1 is associated with favourable outcome and inhibits cell survival in neuroblastoma.
Nowacki S; Skowron M; Oberthuer A; Fagin A; Voth H; Brors B; Westermann F; Eggert A; Hero B; Berthold F; Fischer M
Oncogene; 2008 May; 27(23):3329-38. PubMed ID: 18084322
[TBL] [Abstract][Full Text] [Related]
16. Application of expression genomics for predicting treatment response in cancer.
Chin KV; Alabanza L; Fujii K; Kudoh K; Kita T; Kikuchi Y; Selvanayagam ZE; Wong YF; Lin Y; Shih WC
Ann N Y Acad Sci; 2005 Nov; 1058():186-95. PubMed ID: 16394136
[TBL] [Abstract][Full Text] [Related]
17. The power of NGS technologies to delineate the genome organization in cancer: from mutations to structural variations and epigenetic alterations.
Schweiger MR; Kerick M; Timmermann B; Isau M
Cancer Metastasis Rev; 2011 Jun; 30(2):199-210. PubMed ID: 21267768
[TBL] [Abstract][Full Text] [Related]
18. High-throughput genomic technology in research and clinical management of breast cancer. Evolving landscape of genetic epidemiological studies.
Low YL; Wedrén S; Liu J
Breast Cancer Res; 2006; 8(3):209. PubMed ID: 16834767
[TBL] [Abstract][Full Text] [Related]
19. Genetic stratification of neuroblastoma for treatment tailoring.
Jeison M; Yaniv I; Ash S
Future Oncol; 2011 Sep; 7(9):1087-99. PubMed ID: 21919696
[TBL] [Abstract][Full Text] [Related]
20. Evidence for a hereditary neuroblastoma predisposition locus at chromosome 16p12-13.
Maris JM; Weiss MJ; Mosse Y; Hii G; Guo C; White PS; Hogarty MD; Mirensky T; Brodeur GM; Rebbeck TR; Urbanek M; Shusterman S
Cancer Res; 2002 Nov; 62(22):6651-8. PubMed ID: 12438263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
